Medical Policy
Magnetic Resonance Imaging–Targeted Biopsy of the Prostate

Table of Contents
- Policy: Commercial
- Policy: Medicare
- Authorization Information
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References

Policy Number: 747
BCBSA Reference Number: 7.01.152
NCD/LCD: N/A

Related Policies
- Saturation Biopsy for Diagnosis and Staging of Prostate Cancer, #307
- Focal Treatments for Prostate Cancer, #733

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity
Medicare HMO BlueSM and Medicare PPO BlueSM Members

Magnetic resonance imaging–targeted biopsy of the prostate may be considered MEDICALLY NECESSARY for diagnosis and active surveillance of prostate cancer.

Prior Authorization Information
Inpatient
- For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.

Outpatient
- For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient.

<table>
<thead>
<tr>
<th></th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>Prior authorization is not required.</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>Prior authorization is not required.</td>
</tr>
<tr>
<td>Medicare HMO BlueSM</td>
<td>Prior authorization is not required.</td>
</tr>
<tr>
<td>Medicare PPO BlueSM</td>
<td>Prior authorization is not required.</td>
</tr>
</tbody>
</table>
**CPT Codes / HCPCS Codes / ICD Codes**

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

There is no specific CPT code for this procedure.

**Description**

**PROSTATE CANCER**

Prostate cancer is the most commonly diagnosed cancer and the third leading cause of cancer deaths among men in the United States, with an estimated 161,360 new cases and 26,730 deaths in 2017.¹

**Diagnosis**

The diagnosis and grading of prostate cancer are performed by taking a biopsy of the prostate gland. A prostate biopsy typically is performed in men who have an elevated prostate-specific antigen level or who present with symptoms. The purpose of the biopsy is to determine whether cancer is present and to determine tumor grade. Tumor grade (as measured by the Gleason score) is a major determinate in whether a patient is eligible for active surveillance (lower grade tumors) or a factor for determining definitive intervention (higher grade tumors). Patients on active surveillance undergo periodic follow-up prostate biopsies to assess cancer progression (upgrading of Gleason score).

Prostate biopsies are currently performed using transrectal ultrasound (TRUS) guidance with a 12-core sampling strategy. TRUS was introduced in the late 1980s; with this technique, tissue cores are obtained systematically under ultrasound guidance throughout the whole prostate, although this approach still represents blind biopsy of the prostate as to the location of possible cancer. Before 12-core sampling, 6-core (sextant) sampling was thought to miss too many cases of cancer. However, the 12-core sampling method may overdiagnose clinically insignificant disease and underdiagnose clinically significant disease. Compared with subsequent prostatectomy, TRUS underestimates tumor grade up to 40% of the time and too often detects clinically insignificant disease.

Therefore, the ideal biopsy strategy would only identify men with prostate cancer of clinical significance to direct interventional therapy, and to minimize the detection of clinically insignificant prostate cancer and the risk of consequent overtreatment.

For men undergoing an initial biopsy for an elevated prostate-specific antigen, the systematic 12-core TRUS biopsy detection rate for prostate cancer is approximately 40% to 45%. If an initial 12-core biopsy is negative, and there is still a clinical suspicion of cancer, subsequent serial 12-core biopsies may detect cancer, or, other biopsy techniques such as transperineal template-guided saturation biopsy (in which 30-80 cores are typically obtained) may be used. Saturation biopsy allows for anterior and apical sampling and may detect significant cancer, but also oversamples insignificant types of cancer. In addition, transperineal biopsy requires general anesthesia and is associated with increased morbidity.

**Multiparametric Magnetic Resonance Imaging**

Multiparametric magnetic resonance imaging (MRI) includes anatomic T2-weighted imaging for localization of the normal gland and cancer foci and 2 functional imaging techniques: diffusion-weighted and perfusion imaging. Multiparametric MRI evaluation permits identifying tumor location and extent, oversampling areas of interest, undersampling (or not sampling nontarget areas), and sampling of clinically significant disease (higher grade tumor). T2-weighted images reflect water content of tissues and can define the zonal anatomy of the prostate and the presence of prostate cancer as focal areas of low-signal intensities. The degree of intensity decrease differs with Gleason score; higher Gleason score prostate cancer shows lower signal intensities.² False-positive findings can occur with benign abnormalities including prostatitis, atrophy, fibrosis, gland hyperplasia, or irradiation or hormonal
Diffusion-weighted images measure the random motion of water molecules. Low diffusion coefficients are associated with prostate cancer, and there is an inverse correlation between these values and Gleason score; however, confidence intervals overlap. Perfusion imaging permits assessment of contrast kinetics in focal lesions; prostate tumors typically enhances faster and to a greater extent than the surrounding prostate; however, the nonspecificity of patterns limits the usefulness of this technique in isolation.

Several methods of MRI guidance are available for prostate biopsy: cognitive (or visual), direct (“in-bore”), and MRI-ultrasound fusion (visual targeted or software-based targeted). Image fusion is the process of combining information from more than 1 image into a single image, which may be more informative than any of the images separately. Based on MRI, suspicious areas are identified (ie, regions of interest) and subjected to targeted biopsy.

With the visual method, the ultrasound operator simply aims the biopsy needle at the area of the prostate where prior MRI indicated the lesion. This method requires the MRI unit, a conventional TRUS facility, and an ultrasound operator with no additional training beyond TRUS biopsy. The disadvantage is the potential for human error in the extrapolation from MRI to TRUS without an overlay of the images.

Direct (in-bore) MRI-targeted biopsy requires the MRI tube, fusion of a prior MRI demonstrating a lesion with a contemporaneous MRI to confirm biopsy needle location, and needles introduced into the regions of interest. Serial MRI scans are performed to confirm biopsy needle placement. Studies have demonstrated that in-bore MRI-targeted biopsies have a median cancer detection rate significantly higher than random biopsies; however, this technique is time-consuming and costly, including the in-bore time and the 2 MRI sessions necessary. In addition, only suspicious lesions are sampled, because tissues with a “normal” appearance on MRI are not obtained.

MRI-TRUS fusion biopsy, done visually or using software, superimposes preprocedure (stored) MRI over an intraprocedural (real-time) ultrasound to direct the biopsy needle to an ultrasound region of interest defined by multiparametric MRI.

Table 1 summarizes the MRI requirements for the 3 different MRI-guided prostate biopsy techniques described.

**Table 1. Techniques for MRI-Guided Prostate Biopsy**

<table>
<thead>
<tr>
<th>Method</th>
<th>MRI Requirement(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual</td>
<td>• Prior MRI of prostate lesion</td>
<td>US operator targets the biopsy needle at the area of the prostate where prior MRI indicated a lesion during TRUS</td>
</tr>
<tr>
<td>Direct</td>
<td>• Prior MRI of prostate lesion • Contemporaneous MR images of biopsy needle in prostate lesion location</td>
<td>Fusion of a prior MRI demonstrating a lesion with a contemporaneous MRI to confirm biopsy needle location, and needles introduced into the regions of interest</td>
</tr>
<tr>
<td>MRI-US fusion (visual targeted or software-based targeted)</td>
<td>• Prior MRI of prostate lesion • Overlay of prior MR image over real-time US</td>
<td>Prior MR image superimposed over an intraprocedure (real-time) US to direct the biopsy needle during TRUS</td>
</tr>
</tbody>
</table>

MR: magnetic resonance; MRI: magnetic resonance imaging; TRUS: transrectal ultrasound; US: ultrasound.

Currently, there is evidence comparing these 3 techniques in terms of their ability to detect overall or clinically significant prostate cancer.

Proposed clinical indications for use of MRI-targeted prostate biopsy include: (1) as initial biopsy, (2) rebiopsy after a first negative standard biopsy in men with persistent suspicion of disease, including those with persistently increased prostate-specific antigen levels, suspicious digital rectal exam, previous biopsy with an atypical focus on histology, or extensive high-grade prostatic intraepithelial neoplasia, (3) follow-up for active surveillance to determine initial eligibility for active surveillance and assessing progression.
disease over time, and (4) for local recurrence after radical prostatectomy, after external-beam radiotherapy, or after high-intensity focused ultrasound.

**Summary**

For individuals who have a suspicion of prostate cancer who receive an MRI-targeted biopsy, the evidence includes numerous prospective and retrospective studies of paired cohorts, 2 RCTs and systematic reviews and meta-analyses of these studies comparing MRI-targeted biopsy with TRUS-guided biopsy in detecting overall, clinically significant and insignificant prostate cancers. Relevant outcomes are overall survival, disease-specific survival, test accuracy, morbid events, and quality of life. Studies on the use of MRI-targeted prostate biopsy have shown that the technology may diagnose more clinically significant cancers than TRUS biopsy and fewer clinically insignificant cancers, which might stratify patients for treatment and active surveillance. Considering the prognostic value of risk stratification based on prostate biopsy, better diagnostic accuracy is likely to identify patients more accurately with clinically significant prostate cancer leading to changes in management that would be expected to result in clinically meaningful outcomes in terms of survival or quality of life. The evidence is sufficient to determine that the technology results in a meaningful improvement in net health outcome.

For individuals who have prostate cancer and in active surveillance who receive an MRI-targeted biopsy, the evidence includes a systematic review and observational studies of paired cohorts comparing MRI-targeted biopsy with TRUS biopsy in detecting pathologic progression of prostate cancer in terms of Gleason score and detection of higher grade (Gleason score ≥7) cancer. Relevant outcomes are overall survival, disease-specific survival, test accuracy, morbid events, and quality of life. Current evidence has suggested that, compared with TRUS biopsy, an MRI-targeted biopsy is better at detecting those patients in active surveillance who have progressed and need definitive intervention. With the greater ability to detect prostate cancer with a Gleason score 7 or higher, which is a critical parameter for definitive therapy in prostate cancer, use of this biopsy guidance technique is likely to translate into positive clinically meaningful outcomes (eg, survival, quality of life) in this population. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
</table>

**Information Pertaining to All Blue Cross Blue Shield Medical Policies**

Click on any of the following terms to access the relevant information:

- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

**References**


